- Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
- Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- Adcendo ApS Announces Extension of Series A financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
- Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
- GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
No comments to show.